Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
Phase 1
Terminated
- Conditions
- Allergic ConjunctivitisAllergic Rhinitis
- Interventions
- Biological: Dose Level 1Biological: Dose Level 2Biological: Placebo
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Woodmont Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03038971
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath